Use profile and costs of carbapenemics in an intensive care unit in Distrito Federal – Brazil

• Autor(a) principal: Silva, Heloysa Aurélio
• Data de Publicação: 2021
• Outros Autores: Santana, Rafael Santos, Capucho, Helaine Carneiro, Lima, Ana Paula Paz de, Rocha, Clarisse Lisboa de Aquino, Lima, Rodrigo Fonseca
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/21691
• topic: Farmacoepidemiologia; Gestão de antimicrobianos; Assistência hospitalar.; Pharmacoepidemiology; Antimicrobial stewardship; Hospital care.; Farmacoepidemiología; Programas de Optimización del Uso de los Antimicrobianos; Atención hospitalaria.

Currently, the context of microbial resistance has required management of the use of antimicrobials, especially in the hospital environment. Thus, the aim of this study was to analyze the profile of carbapenems use in the Intensive Care Unit (ICU) of a Brazilian public hospital and the associated costs. To this end, a retrospective observational study of document analysis was carried out, which evaluated medical records, prescriptions and microbiological reports of patients who used carbapenems in 2019. Data from 25 patients with a median age of 65 years and length of hospital stay were 24 days. There were 36 analyzes of the use of carbapenems: 19 (57.8%) referred to the use of meropenem and 17 (47.2%) to the use of ertapenem. The median number of days of use of meropenem was 11 and that of ertapenem was seven. The DDD/1000 patient-days of meropenem had a monthly median of 115.5g (lower when used with ertapenem) and that of ertapenem was 50.7g. The total annual expenditure was R$16,652.00 for meropenem and R$41,072.00 for ertapenem. Sixty microbiological reports were carried out and the most frequent microorganisms were Klebsiella pneumoniae (n=18; 30.0%) and Acinetobacter baumannii complex/haemolyticus (n=14; 23.3%); the overall sensitivity rate was 18.3% for meropenem and 13.6% for ertapenem. The data suggest the need to manage the use of carbapenems considering aspects of the patient and the infectious agent with a potential positive impact on clinical and economic outcomes. For this, proposals for the rational and safe use of antimicrobials must be implemented, emphasizing the importance of each professional in the context of the multidisciplinary team.